After the gene therapy M&A battles of late 2018, Novartis is looking make buy up more preclinical or early stage biotechs like Boston-based IFM Tre.

Boston Biz Journal https://www.bizjournals.com/boston/news/2019/05/23/after-ifm-buy-novartis-looks-to-more-early-stage.html?ana=RSS&s=article_search